Last Tuesday, a patient sat down for a pre-op consult and opened a notes app that ran longer than my operative checklist. She had six “longevity” items on it, including peptides, NAD+ infusions, a supplement stack, and two prescriptions from outside her usual care team. We spent most of the visit doing something much more practical than chasing youth, we sorted what needed to be held, what mattered to anesthesia, and what simply had to be disclosed before surgery.
The right surgeon’s answer to longevity medicine is measured, specific, and sometimes disappointing: some interventions have early biologic signals, a few are being studied seriously, and many are marketed far ahead of outcome data. Before any procedure, patients should tell their surgeon about peptides, rapamycin, NAD+ therapies, supplements, hormones, and anything that could affect bleeding, blood pressure, fasting, immunity, or wound healing.
Clinical judgment matters here because the pre-op conversation is where enthusiasm becomes safety planning. In my clinic, the most useful question is not whether a longevity trend is exciting, it is whether there is enough evidence to justify using it, and enough transparency to keep the operation safe.
Why surgeons hear a different version of the longevity story
I used to think longevity medicine lived in a separate lane from surgical practice. Then I started seeing otherwise healthy aesthetic and reconstructive patients arrive with peptide injections, intermittent rapamycin, high-dose antioxidants, and a kind of confidence that every new molecule was automatically benign. Now I think the lane separation is fake, because the perioperative period exposes the gap between marketing language and physiologic reality.
The honest surgeon’s conversation starts with the patient in front of me, not the social media promise attached to the therapy. If something affects platelet function, immune signaling, hydration, glucose control, or tissue repair, I care immediately. That is true whether the product comes from a compounding pharmacy, a wellness clinic, or a glossy protocol bundled as “optimization.”
For patients who want the credentialed version of that conversation, I point them to my practice background at Dr. Sina Bari, Stanford-trained surgeon. For broader practice information, Sinabari Plastic Surgery is the right starting point.
What the peer-reviewed evidence actually shows
The strongest evidence in longevity medicine still lives in geroscience, not in the influencer layer built on top of it. A 2024 review in Nature Aging summarized the field’s central problem clearly: many geroprotective strategies show promising preclinical effects, but the path from animal signal to human outcome remains uneven. That matters because a signal in a mouse is not the same thing as fewer complications in a person preparing for surgery.
The National Institute on Aging’s 2024 page on clinical trials in healthy aging makes the same point in quieter language. Human trials exist, but they are still relatively limited compared with the volume of marketing. That mismatch is the story, and it is why a clinician should stay skeptical when claims outrun trial design.
Nature Aging is useful because it reminds us that “geroprotector” is a research category, not a patient-proof seal. The Geroscience journal continues to publish mechanistic and translational work, but the field still needs long-term human endpoints, not just biomarker enthusiasm. In practical terms, a molecule can look interesting on a pathway diagram and still be a poor choice before an elective procedure.
I have seen this mismatch up close. A patient may feel better on a regimen and still have no idea whether it changes bleeding risk, anesthetic response, or postoperative inflammation. Those are different questions. Very different.
Which interventions I want to know about before surgery
The short list is bigger than most patients expect. I want to know about peptides, rapamycin or sirolimus use, NAD+ infusions or oral precursors, testosterone and other hormones, injectable “recovery” regimens, stimulant-based fat-loss plans, and supplements that can alter clotting or blood pressure. If a patient takes a longevity product once a week, once a month, or only “when traveling,” I still want it documented.
In pre-op planning, disclosure is the safety step. Some compounds are stopped out of caution, some are reviewed with anesthesia, and some are simply logged because the anesthetic team needs the full medication picture. I would rather spend two extra minutes clarifying a peptide schedule than discover it after a patient arrives fasting and anxious on the morning of surgery.
One patient told me, “I don’t really count those as medications, they’re more like maintenance.” That sentence is exactly why this matters. Maintenance can still change the operation.
NAD+, rapamycin, and peptides, what I actually think
NAD+ is a good example of how the longevity conversation gets ahead of its own evidence. I do not dismiss the biology, and I do not pretend every report is nonsense. I do, however, separate mechanistic plausibility from proven clinical benefit, because a biochemical pathway is not the same thing as a better surgical outcome.
Rapamycin is more complicated. It has real pharmacology, real immunologic effects, and a real history in transplant medicine, which is exactly why I pay attention when patients use it outside that context. I cannot look at an mTOR-modulating drug and assume it is neutral around wound healing, infection risk, or recovery timing. I would not treat it like a vitamin.
Peptides are the broadest and least disciplined category in clinic. Some products are studied in tightly defined research settings, while others are sold with a level of certainty that outpaces their evidence. What I would not do is endorse a peptide stack for a patient heading into elective surgery without knowing the exact compound, dose, source, and timing. That would be lazy medicine.
There is also a deeper clinical vulnerability here, one I think patients appreciate when I say it plainly: I do not always know the answer on first sight. Sometimes I need to look up the exact compound, check its half-life, or call anesthesia. That is not weakness. That is how safe perioperative care works.
How I separate real anti-aging research from marketing
I use a simple filter. First, does the claim come from a human study, and if so, what was measured, in how many people, and for how long. Second, is the outcome a biomarker, a symptom, or a real clinical event like function, complications, or survival. Third, does the proposed use resemble the studied population, or is someone stretching a narrow trial into a universal promise.
If the pitch leans heavily on “mitochondrial support,” “cellular optimization,” or “reversal,” I slow down. Those words can be real scientific shorthand, but they are also favorite marketing costumes. A surgeon learns quickly that credible medicine tends to sound more modest than the ad copy around it.
That is why I prefer sources like the National Institute on Aging trial portfolio and the geroscience literature over wellness summaries. The number of actively studied interventions is real, but the number of proven, broadly applicable longevity therapies is much smaller than the internet suggests.
What a surgeon would actually recommend
I recommend honesty first. Bring the full list, even the embarrassing one, because no one in the operating room benefits from surprise medicine. If a product affects coagulation, immune function, hydration, sedation, or glucose, I want it discussed early enough to make a plan.
I recommend skepticism second. If a clinic promises a lifetime extension story with no clear trial design, no defined endpoint, and no adverse-event discussion, I assume the patient is being sold hope before data. That does not make the person taking it foolish. It means the market is doing what markets do.
I also recommend restraint. I do not think every elective patient needs to experiment with several longevity interventions at once, especially in the weeks leading into surgery. A clean perioperative window is often more valuable than one more speculative protocol. Recovery likes stability.
The clinical conversation I want patients to have instead
When a patient asks me about longevity medicine, I try to translate the question into something more useful. What is the goal, better recovery, lower inflammation, more energy, or simply the reassurance of doing something proactive. Once the goal is clear, the evidence conversation gets easier and the perioperative risk conversation gets honest.
I used to think the best answer was to ignore the longevity trend and stay focused on the operation. Then I watched more than one consult get derailed by a medication list that should have been reviewed weeks earlier. Now I think the better answer is to engage early, because early engagement protects the case and respects the patient’s curiosity.
That is also where surgeon perspective helps. I am not selling the patient a protocol. I am looking at tissue, timing, anesthesia, recovery, and risk in the same room.
Back to the patient in my office
By the end of last Tuesday’s consult, the patient’s notes app looked less glamorous and more useful. We had a plan for what to hold, what to continue, and what to review with anesthesia. The room felt calmer.
That is the real value of a surgeon’s view of longevity medicine. It keeps the conversation anchored in what can be measured, what can be verified, and what actually matters when a person is about to undergo a procedure. The honest answer is often less exciting than the headline. It is also safer.
Frequently asked questions
Should I tell my plastic surgeon if I take NAD+ infusions or supplements?
Yes, and you should tell the surgeon before the operation date is set if possible. NAD+ products may not always create a direct surgical contraindication, but the full medication list helps the team assess anesthesia, hydration, and perioperative planning. I want the exact product name, dose, and how recently you used it.
Does rapamycin affect wound healing after surgery?
It can, depending on dose, timing, and why it is being used. Rapamycin has real immunologic effects, so I do not treat it like a benign wellness supplement around elective surgery. If a patient is taking it, I review the timing carefully and often coordinate with anesthesia or the prescribing clinician.
What longevity supplements should I stop before cosmetic surgery?
The right answer depends on the ingredient, but anything that can affect bleeding, blood pressure, sedation, or clotting deserves review. I especially want to know about stimulant weight-loss products, high-dose herbal blends, and any injectable regimen from a longevity clinic. Bring the bottle, the label, or a photo of both.
How do I know if a longevity claim is real research or just marketing?
Look for a human study with a clear endpoint, a defined population, and a specific timeframe or sample size. If the claim is based only on animal data, mechanistic theory, or vague language like “cellular renewal,” I stay cautious. Real research usually sounds more modest than promotional copy.
What is Dr. Sina Bari’s approach to longevity medicine before surgery?
I ask for the full list, review it for operative relevance, and separate what is interesting from what is safe. I do not dismiss patient curiosity, but I also do not let enthusiasm outrun evidence or perioperative safety. For patients who want my background, the most direct reference is Dr. Sina Bari, Stanford-trained surgeon.